NEW YORK--(BUSINESS WIRE)--Bioenvision, Inc. (NasdaqGM:BIVN) today announced it has entered into a licensing arrangement with Foster Corporation to license out exclusive rights to manufacture, market and distribute the Company’s proprietary anti-microbial OLIGON® technology. Under the terms of the license agreement, Bioenvision will have a revenue sharing arrangement on future sublicenses and a royalty on all sales by Foster, a Connecticut-based compounder of biomedical materials. Foster also must comply with annual minimum marketing and research and development expenditures within the first five years of the term of the license.
